{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:14:13Z","timestamp":1740107653609,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["302153\/2019-5"],"award-info":[{"award-number":["302153\/2019-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00467-021-05316-0","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T21:37:02Z","timestamp":1634938622000},"page":"499-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children"],"prefix":"10.1007","volume":"37","author":[{"given":"Pedro Alves Soares","family":"Vaz de Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia","family":"Bitencourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno Wilnes Simas","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananda Queiroz Rocha","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique Santos","family":"Hermida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Roberto","family":"Moreira Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Dinamarco","family":"Mestriner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-3882","authenticated-orcid":false,"given":"Ana Cristina","family":"Sim\u00f5es e Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"5316_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00467-018-4189-7","volume":"35","author":"A Cambier","year":"2020","unstructured":"Cambier A, Boyer O, Deschenes G, Gleeson J, Couderc A, Hogan J et al (2020) Steroid therapy in children with IgA nephropathy. Pediatr Nephrol 35:359\u2013366. https:\/\/doi.org\/10.1007\/s00467-018-4189-7","journal-title":"Pediatr Nephrol"},{"key":"5316_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrneph.2012.58","volume":"8","author":"KN Lai","year":"2012","unstructured":"Lai KN (2012) Pathogenesis of IgA nephropathy. Nat Rev Nephrol 8:275\u2013283. https:\/\/doi.org\/10.1038\/nrneph.2012.58","journal-title":"Nat Rev Nephrol"},{"key":"5316_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00467-020-04486-7","volume":"36","author":"R Coppo","year":"2021","unstructured":"Coppo R (2021) Treatment of IgA nephropathy in children: a land without KDIGO guidance. Pediatr Nephrol 36:491\u2013496. https:\/\/doi.org\/10.1007\/s00467-020-04486-7","journal-title":"Pediatr Nephrol"},{"key":"5316_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00467-007-0726-5","volume":"23","author":"N Yata","year":"2008","unstructured":"Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M et al (2008) Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol 23:905\u2013912. https:\/\/doi.org\/10.1007\/s00467-007-0726-5","journal-title":"Pediatr Nephrol"},{"key":"5316_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ekir.2018.07.021","volume":"3","author":"DT Selewski","year":"2018","unstructured":"Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y et al (2018) Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN study. Kidney Int Rep 3:1373\u20131384. https:\/\/doi.org\/10.1016\/j.ekir.2018.07.021","journal-title":"Kidney Int Rep"},{"key":"5316_CR6","first-page":"694","volume":"74","author":"J Berger","year":"1968","unstructured":"Berger J, Hinglais N (1968) Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 74:694\u2013695","journal-title":"J Urol Nephrol (Paris)"},{"key":"5316_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/j.1523-1755.2004.00486.x","volume":"65","author":"Y Xie","year":"2004","unstructured":"Xie Y, Chen X, Nishi S, Narita I, Gejyo F (2004) Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int 65:1135\u20131144. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00486.x","journal-title":"Kidney Int"},{"key":"5316_CR8","first-page":"147","volume":"51","author":"FM Rasche","year":"1999","unstructured":"Rasche FM, Schwarz A, Keller F (1999) Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 51:147\u2013152","journal-title":"Clin Nephrol"},{"key":"5316_CR9","first-page":"72","volume":"33","author":"R Coppo","year":"1990","unstructured":"Coppo R, Roccatello D, Amore A, Quattrocchio G, Molino A, Gianoglio B et al (1990) Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol 33:72\u201386","journal-title":"Clin Nephrol"},{"key":"5316_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00467-016-3390-9","volume":"32","author":"R Coppo","year":"2017","unstructured":"Coppo R (2017) Biomarkers and targeted new therapies for IgA nephropathy. Pediatr Nephrol 32:725\u2013731. https:\/\/doi.org\/10.1007\/s00467-016-3390-9","journal-title":"Pediatr Nephrol"},{"key":"5316_CR11","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","volume":"18","author":"R Coppo","year":"2007","unstructured":"Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R et al (2007) IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880\u20131888. https:\/\/doi.org\/10.1681\/ASN.2006040347","journal-title":"J Am Soc Nephrol"},{"key":"5316_CR12","first-page":"55","volume":"61","author":"N Ohashi","year":"2009","unstructured":"Ohashi N, Urushihara M, Kobori H (2009) Activated intrarenal reactive oxygen species and renin angiotensin system in IgA nephropathy. Minerva Urol Nefrol 61:55\u201366","journal-title":"Minerva Urol Nefrol"},{"key":"5316_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00467-018-4099-8","volume":"34","author":"Y Shima","year":"2019","unstructured":"Shima Y, Nakanishi K, Sako M, Saito-Oba M, Hamasaki Y, Hataya H et al (2019) Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). Pediatr Nephrol 34:837\u2013846. https:\/\/doi.org\/10.1007\/s00467-018-4099-8","journal-title":"Pediatr Nephrol"},{"key":"5316_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"5316_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/jebm.12266","volume":"10","author":"A Paez","year":"2017","unstructured":"Paez A (2017) Gray literature: an important resource in systematic reviews. J Evid-Based Med 10:233\u2013240. https:\/\/doi.org\/10.1111\/jebm.12266","journal-title":"J Evid-Based Med"},{"key":"5316_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"5316_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"5316_CR18","unstructured":"National Heart, Lung and Blood Institute (2014) Quality assessment tool for case series studies. https:\/\/www.nhlbi.nih.gov\/health-pro\/guidelines\/in-develop\/cardiovascularriskreduction\/tools\/case_series 2014. Accessed 20 July 2021."},{"key":"5316_CR19","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 20 July 2021."},{"key":"5316_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5414\/cnp64035","volume":"64","author":"Y Yang","year":"2005","unstructured":"Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A et al (2005) Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol 64:35\u201340. https:\/\/doi.org\/10.5414\/cnp64035","journal-title":"Clin Nephrol"},{"key":"5316_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s10157-003-0255-x","volume":"7","author":"K Yagi","year":"2003","unstructured":"Yagi K, Okada M, Yanagida H, Kuwajima H, Ikeda M, Sugimoto K et al (2003) Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy. Clin Exp Nephrol 7:270\u2013274. https:\/\/doi.org\/10.1007\/s10157-003-0255-x","journal-title":"Clin Exp Nephrol"},{"key":"5316_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1442-200x.2004.01955.x","volume":"46","author":"H Tanaka","year":"2004","unstructured":"Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K et al (2004) Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int 46:576\u2013579. https:\/\/doi.org\/10.1111\/j.1442-200x.2004.01955.x","journal-title":"Pediatr Int"},{"key":"5316_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00467-008-1006-8","volume":"24","author":"K Nakanishi","year":"2009","unstructured":"Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M et al (2009) Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol 24:845\u2013849. https:\/\/doi.org\/10.1007\/s00467-008-1006-8","journal-title":"Pediatr Nephrol"},{"key":"5316_CR24","doi-asserted-by":"publisher","first-page":"147032031664724","DOI":"10.1177\/1470320316647240","volume":"17","author":"Y Pei","year":"2016","unstructured":"Pei Y, Xu Y, Ruan J, Rong L, Jiang M, Mo Y et al (2016) Plasma oxidative stress level of IgA nephropathy in children and the effect of early intervention with angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 17:1470320316647240. https:\/\/doi.org\/10.1177\/1470320316647240","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"5316_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1067\/mpd.2000.103448","volume":"136","author":"BJ Foster","year":"2000","unstructured":"Foster BJ, Bernard C, Drummond KN, Sharma AK (2000) Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr 136:370\u2013375. https:\/\/doi.org\/10.1067\/mpd.2000.103448","journal-title":"J Pediatr"},{"key":"5316_CR26","first-page":"1","volume":"49","author":"R Katafuchi","year":"1998","unstructured":"Katafuchi R, Kiyoshi Y, Oh Y, Uesugi N, Ikeda K, Yanase T et al (1998) Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation. Clin Nephrol 49:1\u20138","journal-title":"Clin Nephrol"},{"key":"5316_CR27","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1742-1241.2009.02038.x","volume":"63","author":"J Cheng","year":"2009","unstructured":"Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH (2009) ACEI\/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract 63:880\u2013888. https:\/\/doi.org\/10.1111\/j.1742-1241.2009.02038.x","journal-title":"Int J Clin Pract"},{"key":"5316_CR28","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s10157-013-0921-6","volume":"18","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y (2014) Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol 18:770\u2013777. https:\/\/doi.org\/10.1007\/s10157-013-0921-6","journal-title":"Clin Exp Nephrol"},{"key":"5316_CR29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/j.1742-1241.2012.02970.x","volume":"66","author":"J Cheng","year":"2012","unstructured":"Cheng J, Zhang X, Tian J, Li Q, Chen J (2012) Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract 66:917\u2013923. https:\/\/doi.org\/10.1111\/j.1742-1241.2012.02970.x","journal-title":"Int J Clin Pract"},{"key":"5316_CR30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00004872-199609002-00001","volume":"14","author":"K Arakawa","year":"1996","unstructured":"Arakawa K (1996) Serine protease angiotensin II systems. J Hypertens Suppl 14:S3\u2013S7","journal-title":"J Hypertens Suppl"},{"key":"5316_CR31","doi-asserted-by":"publisher","first-page":"H2274","DOI":"10.1152\/ajpheart.1995.268.6.H2274","volume":"268","author":"PJ Pagano","year":"1995","unstructured":"Pagano PJ, Ito Y, Tornheim K, Gallop PM, Tauber AI, Cohen RA (1995) An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol 268:H2274\u2013H2280. https:\/\/doi.org\/10.1152\/ajpheart.1995.268.6.H2274","journal-title":"Am J Physiol"},{"key":"5316_CR32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.bbrc.2007.04.105","volume":"358","author":"H Kobori","year":"2007","unstructured":"Kobori H, Katsurada A, Ozawa Y, Satou R, Miyata K, Hase N, Suzaki Y, Shoji T (2007) Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun 358:156\u2013163. https:\/\/doi.org\/10.1016\/j.bbrc.2007.04.105","journal-title":"Biochem Biophys Res Commun"},{"key":"5316_CR33","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1440-1681.2009.05172.x","volume":"36","author":"N Ohashi","year":"2009","unstructured":"Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, Urushihara M, Kobori H (2009) Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice. Clin Exp Pharmacol Physiol 36:750\u2013755. https:\/\/doi.org\/10.1111\/j.1440-1681.2009.05172.x","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"5316_CR34","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/j.1751-7176.2011.00508.x","volume":"13","author":"JL Izzo Jr","year":"2011","unstructured":"Izzo JL Jr, Weir MR (2011) Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 13:667\u2013675. https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00508.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"5316_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","volume":"47","author":"PK Li","year":"2006","unstructured":"Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group (2006) Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47:751\u2013760. https:\/\/doi.org\/10.1053\/j.ajkd.2006.01.017","journal-title":"Am J Kidney Dis"},{"key":"5316_CR36","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1210\/endo-129-2-823","volume":"129","author":"I Kifor","year":"1991","unstructured":"Kifor I, Moore TJ, Fallo F, Sperling E, Chiou CY, Menachery A, Williams GH (1991) Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology 129:823\u2013831. https:\/\/doi.org\/10.1210\/endo-129-2-823","journal-title":"Endocrinology"},{"key":"5316_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160:685\u2013693. https:\/\/doi.org\/10.1001\/archinte.160.5.685","journal-title":"Arch Intern Med"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05316-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05316-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T15:26:58Z","timestamp":1647271618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05316-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5316"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05316-0","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"type":"print","value":"0931-041X"},{"type":"electronic","value":"1432-198X"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"12 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}